REVENIO

Invitation to Revenio Group's Capital Markets Day 2023

Revenio Group Corporation, Press release, October 2, 2023 at 2.00 p.m. (EEST)

Revenio Group is pleased to invite analysts, institutional investors and other capital market representatives to the Capital Markets Day on Thursday, November 30, 2023 from 2:00 p.m. The event will take place in Sanomatalo (Töölönlahdenkatu 2) in Helsinki and will last approximately three hours.

On Capital Markets Day, the company's key personnel create an in-depth overview of Revenio's strategy, finances, markets, products and operations. The day will include presentations by CEO Jouni Toijala, CFO Robin Pulkkinen and other members of the Leadership team.

Anyone can follow the event via a live webcast at https://revenio.videosync.fi/cmd2023/. The presentation materials and the recording of the event will be available at www.reveniogroup.com/en/investors/cmd_2023 after the event. The Capital Markets Day and all materials are in English.

It is possible to ask questions to Revenio's management throughout the event via the webcast.

The detailed program will be published on www.reveniogroup.com/en/investors/cmd_2023 closer to the event.

Registration and more information

In order to attend the event at Sanomatalo, please register via email to elina.kari@revenio.fi by Monday, November 20 at the latest. The number of seats is limited, so we recommend registering early. You do not need to register for the webcast in advance. If you have any questions regarding the event, please contact Revenio's investor relations at ir@revenio.fi.

We warmly welcome you to our Capital Markets Day!

For further information, please contact

Jouni Toijala, President & CEO, tel. +358 50 484 0085 jouni.toijala@revenio.fi

Robin Pulkkinen, CFO, tel. +358 50 505 9932 robin.pulkkinen@revenio.fi

Distribution

Principal media www.reveniogroup.fi/en/

REVENIO

Revenio Group in brief

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2022, the Group's net sales totaled EUR 97.0 million, with an operating profit of EUR 29.7 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

Invitation to Revenio Group's Capital Markets Day 2023